Results 131 to 140 of about 75,323 (218)

Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients [PDF]

, 2013
Bearzi Italo, Bianconi Maristella, Bittoni Alessandro, Cascinu Stefano, Cecchini Luca, Del Prete Michela, Faloppi Luca, Giampieri Riccardo, Guerrieri Mario, Lezoche Giovanni, Loretelli Cristian, Mandolesi Alessandra, Piva Francesco, Scartozzi Mario   +13 more
core   +1 more source

A review of the current evidence for maintenance therapy in gastric cancer. [PDF]

Front Pharmacol
Han X, Zhang Y, Fan Q, Yu J, Lv L, Li Y, Hou L.   +6 more
europepmc   +1 more source

Preoperative Chemoradiotherapy with Tegafur-Uracil, Capecitabine, or 5-Fluorouracil/Leucovorin for Rectal Cancer in an Asian Cohort: A Real-World Comparison from the Pre-TNT Era. [PDF]

Curr Oncol
Dai KY, Chen FY, Liu CK, Lin J, Liu SH.
europepmc   +1 more source

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Jhaveri K, Loi S, Hamilton E, Schmid P, Anders CK, Testa L, Wildiers H, Tseng LM, Lu YS, Park YH, Im SA, Chen SC, Young RR, Lloyd C, Wrona M, Zhang C, Carroll D, André F.   +17 more
europepmc   +1 more source

Recurrent hyperammonemic encephalopathy in a breast cancer patient receiving capecitabine therapy: a case report and literature review. [PDF]

Front Pharmacol
Mu Y, Li Q, Kong J, Zhao Y.
europepmc   +1 more source

CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL. [PDF]

Transl Breast Cancer Res
Tokunaga E.
europepmc   +1 more source

In silico identification of bilobetin and ginsenoside as dual CK2 and ULK2 inhibitors targeting triple-negative breast cancer. [PDF]

Sci Rep
Hossain MA, Tamanna IJ, Hossain MS, Parvez A, Afrin S, Sobuj DR, Islam MT, Al Noman A, Ahmed M, Sultana S, Srivastava S, Rao GSNK, Khan SR, Babu MR, Tariq M, Saiyad MT, Hamzah Z, Jain M.   +17 more
europepmc   +1 more source

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2⁺ breast cancer: TBCRC049 phase 2 study results. [PDF]

Nat Cancer
Murthy RK, O'Brien BJ, Berry DA, Singareeka-Raghavendra A, Monroe MG, Johnson J, White J, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Riley K, Melisko M, Morikawa A, Ferguson SD, de Groot JF, Krop IE, Valero V, Rimawi MF, Wolff AC, Tripathy D, Lin NU, Stringer-Reasor EM.   +21 more
europepmc   +1 more source

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study. [PDF]

Front Pharmacol
Baskarane H, Divakar MK, Santhosh AP, Pallavi K, Hooda V, Yenamandra VK, Kumar S, Shetty V, Banotra J, Gupta I, Minocha S, Tanwar P, Sharma A, Vasudeva P, Kumar A, Chethan R, Bakhshi S, Batra A.   +17 more
europepmc   +1 more source

Metastatic Colorectal Cancer as a Chronic Disease: Twelve-Year Survival After Initially Unresectable Bilobar Liver Metastases. [PDF]

Cureus
Mathew T, Smith S, George M.
europepmc   +1 more source